Novartis moved to expand its allergy and immunology pipeline by acquiring Excellergy. The purchase targets Exl-111, an anti-IgE antibody currently in Phase I testing, with potential applications across immune and inflammatory conditions including food allergy, allergic asthma, and chronic spontaneous or chronic inducible urticaria. Dealmaking reflects ongoing interest in upstream discovery assets that can be developed into clinical programs and then leveraged across immunology indications. For Novartis, the acquisition is a targeted bet in antibody-based therapies rather than a broad platform purchase.